INTRODUCTION
It is not fully clear what is the clinical utility of continuous blood lipid testing in clinical practice. In page 4, line 41-43, authors state that blood lipid testing is used for monitoring response to the therapy. Does that mean that in Australia lipid targets are used? I feel that paragraph 3 and 4 of introduction can be combined and summarized in order to shorten the Introduction. 
METHODS
The selection criteria for the study population seems fair. Thanks for the detailed explanation.
Page 5, line 39-42: I am not sure that this particular population can be considered as representative of the full Australian population. It seems to me, based on the description, that the study population (de-identified 10% sample of PBS and MBS) could be a quite particular population. Please provide more evidence that this population can be representative of the full population as you indicate.
RESULTS
Are the descriptive measures in Table 1 statistically significant different?
Please provide the rate of correct utilization of HDL-C testing in the overall study population.
Could you provide p-value for the trend in prevalence of underutilization and overutilization of HDL-C tests from 2008-2014.
DISCUSSION
Even though the guidelines remained the same since 2007, is there any other factor that could have changed the clinical practice that could affect the results?
REVIEWER
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GENERAL COMMENTS
professional statistical input is required as the validity of the the whole study is dependent on the statistical corrections done to overcome study weaknesses REVIEWER Giuseppe Biondi-Zoccai Sapienza University of Rome, Latina, Italy REVIEW RETURNED 10-Oct-2017
The authors report an interesting study on under and overprescribing of HDL testing in Australia. Despite the work strengths, I recommend adding a sensitivity analysis using missing data imputation, instead of complex but potentially biased formulas to impute over and underprescribing.
VERSION 1 -AUTHOR RESPONSE
Note: All page and paragraph numbers refer to the mark-up version of the manuscript. Note: a Word version of this response has been attached for ease of reading.
======================================================================== Editorial Requirements:
Comment 1: Please revise your title to state the research question, study design, and setting (location). This is the preferred format for the journal.
Authors' Response:
The title has been revised according to the journal's format.
Changes to the manuscript:
The title has been revised as below: "Patterns and trends of potentially inappropriate high-density lipoprotein-cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 through 2014: analysis of linked individual patient data from the Australian Medicare Benefit Schedule and Pharmaceutical Benefit Schemes." We have added text to explain the different reasons for lipid testing in clinical practice, including monitoring response to therapy (short term and long term) to meet recommended lipid targets. The GP 'Redbook" recommends the following lipid targets after starting treatment: "Lipid-lowering therapy for primary prevention should (while balancing risks and benefits) aim towards:
Changes to the manuscript: Page 4, Paragraph 3: The following text has been added: "Blood lipid testing is used by general practitioners and medical specialists for two main purposes: [21] (i) identifying patients at high CVD risk in order to offer lipid lowering treatment (who may or may not also have high blood cholesterol), and (ii) for monitoring response to the treatment after this has been prescribed, [22] aiming recommended lipid targets.
[18]" ----------------------------------------Comment 2:
I feel that paragraph 3 and 4 of introduction can be combined and summarized in order to shorten the Introduction.
Authors' Response:
We agree that these two paragraphs were unnecessarily long. Therefore, we have presented the same information in a more logical and concise way; the word count has been reduced from 302 to 220.
Changes to the manuscript: Page 4, Paragraph 3: The changes have been done. We have been using Australian terminology where "Pathology services" means "pathology tests".
----------------------------------------
Changes to the manuscript: All "pathology services" in the paper have been replaced with "pathology tests" in order to make it clearer to international audiences.
----------------------------------------Comment 4:
Page 5, line 39-42: I am not sure that this particular population can be considered as representative of the full Australian population. It seems to me, based on the description, that the study population (deidentified 10% sample of PBS and MBS) could be a quite particular population. Please provide more evidence that this population can be representative of the full population as you indicate.
Authors' Response:
The Australian Department of Health has been very clear in the dataset's documentation that this sample is representative of the Australian population when the provided observation weights are used in the calculations. Unfortunately, the documentation of the dataset is not available online. However, we will be happy to share it with the reviewer if requested.
Changes to the manuscript: Page 6, Paragraph 2: The following sentence has been added: "The dataset contains weights that allow accurate estimation of service use (not only at the national level, but also at the level of gender, age, and geography), making the dataset representative of the Australian population."
Are the descriptive measures in Table 1 statistically significant different? Authors' Response:
We agree with the reviewer that it is important to quantify the uncertainty in the observed patterns. Therefore, we decided to leave the raw, unadjusted estimates in Table 1 and add a new table (Table  2) . Table 2 reports the results of a multivariate analysis for two dependent variables: the estimated number of HDL-C tests and the observed number of lipid-lowering medications. It shows how much variation can be attributed to individual characteristics such as age, gender, and location and whether there are significant differences among the groups defined by those variables.
Changes to the manuscript: Page 15: Table 2 and related description have been added.
We have added the rate of the correct utilisation to the "Result" Section in Figure 2 accordingly.
Changes to the manuscript: Page 17: The rate of the correct utilisation has been added to Figure 2 . Also, the description text of the correct utilisation rate has been added. Page 18: Figure 3 has been replotted to be consistent with Figure 2 .
We computed p-values for the linear trend in the prevalence of under-and overutilization as suggested. Their values are 0.228 and 0.21, respectively. However, these does not necessarily exclude the possibility that in recent years there is an upward and a downward trend in under-and overutilization, respectively. Just looking at the data, it seems that year 2008 or 2009 may be anomalous. If we only look at the most recent five years, we would conclude that those trends exist. However, those time series are too short, and no matter what p-value we found we do not feel confident in making quantitative statement. In the rest of the paper, we talk about trends, but we clarify that there is only suggestive evidence for them.
Changes to the manuscript: Page 16, Paragraph 1: We added the following sentence: "A simple trend analysis shows no significant linear trend for any of the utilisation curves for the period between 2008 and 2014, with pvalues for the trend over 0.2. However, an analysis of the most recent years suggests that there is an upward trend for underutilisation and downward trend for overutilization. Given the very limited lengths of the time series, it does not seem appropriate to draw any definite conclusion and take the presence of these trends as suggestive." ----------------------------------------Comment 8: Even though the guidelines remained the same since 2007, is there any other factor that could have changed the clinical practice that could affect the results?
